O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.
Viral and H1N1 Infections – Pipeline Review,H1 2013Viral Infection and H1N1 Infection are 2 different report studies by Gl...
Report Details:Published: March 2013Price: Single User License: US$2000   Corporate User License: US$ 6000Table of Content...
Próximos SlideShares
Carregando em…5
×

0

Compartilhar

Baixar para ler offline

Viral and h1 n1 Infections Market– pipeline review, h1 2013

Baixar para ler offline

  • Seja a primeira pessoa a gostar disto

Viral and h1 n1 Infections Market– pipeline review, h1 2013

  1. 1. Viral and H1N1 Infections – Pipeline Review,H1 2013Viral Infection and H1N1 Infection are 2 different report studies by Global Markets Direct. It provides anoverview of the indication’s therapeutic pipeline. These reports provide information on the therapeuticdevelopment for Viral and H1N1 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development forViral and H1N1 Infection.Scope- A snapshot of the global therapeutic scenario for Viral and H1N1.- A review of the Viral and H1N1products under development by companies and universities/researchinstitutes based on information derived from company and industry-specific sources.- Coverage of products based on various stages of development ranging from discovery till registrationstages.- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.- Coverage of the Viral and H1N1 Infection pipeline on the basis of route of administration and moleculetype.- Key discontinued pipeline projects.- Latest news and deals relating to the products.Reasons to buy- Identify and understand important and diverse types of therapeutics under development for Viral andH1N1Infection.- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.- Devise corrective measures for pipeline projects by understanding Viral and H1N1 Infection pipelinedepth and focus of Indication therapeutics.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners withthe most attractive projects to enhance and expand business potential and scope.- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factorsthat drove them from pipeline.Check out complete Viral Infection Pipeline review @http://www.reportsnreports.com/reports/228413-viral-infections-pipeline-review-h1-2013.htmlGet a copy of H1N1 Infection Pipeline review market with comprehensive Table of Contents @http://www.reportsnreports.com/reports/228412-h1n1-infection-pipeline-review-h1-2013.html
  2. 2. Report Details:Published: March 2013Price: Single User License: US$2000 Corporate User License: US$ 6000Table of Contents:List of Figures - H1N1 Infection – Pipeline Review, H1 2013Number of Products under Development for H1N1 Infection, H1 2013 14Products under Development for H1N1 Infection – Comparative Analysis, H1 2013 15Products under Development by Companies, H1 2013 16Products under Investigation by Universities/Institutes, H1 2013 20Late Stage Products, H1 2013 21Mid Clinical Stage Products, H1 2013 22Early Clinical Stage Products, H1 2013 23Discovery and Pre-Clinical Stage Products, H1 2013 24Assessment by Monotherapy Products, H1 2013 66Assessment by Combination Products, H1 2013 67Assessment by Route of Administration, H1 2013 68Assessment by Stage and Route of Administration, H1 2013 69Assessment by Molecule Type, H1 2013 70Assessment by Stage and Molecule Type, H1 2013 71List of Figures - Viral Infections – Pipeline Review, H1 2013Number of Products under Development for Viral Infections, H1 2013 33Products under Development for Viral Infections – Comparative Analysis, H1 2013 34Products under Development by Companies, H1 2013 35Products under Investigation by Universities/Institutes, H1 2013 58Late Stage Products, H1 2013 63Mid Clinical Stage Products, H1 2013 64Early Clinical Stage Products, H1 2013 65Discovery and Pre-Clinical Stage Products, H1 2013 66Assessment by Monotherapy Products, H1 2013 372Assessment by Combination Products, H1 2013 373Assessment by Route of Administration, H1 2013 374Assessment by Stage and Route of Administration, H1 2013 375Assessment by Molecule Type, H1 2013 377Assessment by Stage and Molecule Type, H1 2013 378Contact sales@reportsandreports.com for further information.

Vistos

Vistos totais

153

No Slideshare

0

De incorporações

0

Número de incorporações

1

Ações

Baixados

0

Compartilhados

0

Comentários

0

Curtir

0

×